Chronic administration of imipramine decreases freezing time in rats genetically predisposed to catalepsy.

Bull Exp Biol Med

Laboratory for Neurogenomics of Behavior, Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk.

Published: October 2004

The effects of acute and chronic imipramine treatment on the degree of catalepsy were compared in GC rats genetically predisposed to catalepsy. We recorded the time over which the rats remained in a vertical position they were placed. As differentiated from acute treatment, chronic administration of imipramine dose-dependently decreased the time of freezing in GC rats.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10517-005-0111-yDOI Listing

Publication Analysis

Top Keywords

chronic administration
8
administration imipramine
8
time rats
8
rats genetically
8
genetically predisposed
8
predisposed catalepsy
8
imipramine decreases
4
decreases freezing
4
freezing time
4
rats
4

Similar Publications

Cellular and gene therapy (CGT) products have emerged as a popular approach in regenerative medicine, showing promise in treating various pancreatic and liver diseases in numerous clinical trials. Before these therapies can be tested in human clinical trials, it is essential to evaluate their safety and efficacy in relevant animal models. Such preclinical testing is often required to obtain regulatory approval for investigational new drugs.

View Article and Find Full Text PDF

Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway.

Eur J Pharmacol

January 2025

State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, College of Pharmacy, and Department of Cardiology, the Second Affiliated Hospital, Harbin Medical University, Harbin 150081, China; State Key Labratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, and Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin 150081, China; Research Unit of Noninfectious Chronic Diseases in Frigid Zone (2019RU070), Chinese Academy of Medical Sciences, Harbin 150081, China. Electronic address:

Hyperlipidemia is a major risk factor for hypertension, coronary heart disease, diabetes and stroke, triggering an intensified research efforts into its prevention and treatment. Tetrahydroberberrubine (THBru) is a derivative of berberine (BBR) that has been shown to have higher bioavailability and lower toxicity compared to its parent compound. However, its impact on hyperlipidemia has not been fully explored.

View Article and Find Full Text PDF

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis.

Braz J Otorhinolaryngol

January 2025

Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan.

Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10% of ECRS cases has concomitant EOM, concomitant EOM improvement has been observed when dupilumab is administered for ECRS.

View Article and Find Full Text PDF

Background: Axial Spondyloarthritis (axSpA) is a chronic inflammatory rheumatic condition affecting the axial skeleton, leading to pain, stiffness, and fatigue. While biologic therapies have improved clinical management, many patients experience partial or no responses, resulting in delays in disease control. Additionally, the risk of adverse events and increased costs remains a concern.

View Article and Find Full Text PDF

Effects of Ab501 (certolizumab mice equivalent) in arthritis induced bone loss.

ARP Rheumatol

January 2024

Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Portugal.

Introduction - Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease, which causes local and systemic bone damage. The main goal of this work was to analyze, how treatment intervention with Ab501 (certolizumab mice equivalent) prevents the disturbances on bone structure and mechanics induced by arthritis. Methods - Thirty DBA/1 collagen-induced arthritis (CIA) mice were randomly housed in experimental groups, as follows: arthritic untreated (N=9), preventive intervention (N=10) and treatment intervention (N=11).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!